CARMAT Announces the Approval of All Resolutions Supported by the Board of Directors at Its Annual General Meeting

Regulatory News:

CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, informs its shareholders that the annual general meeting (AGM) of May 11, 2022 was able to deliberate, the quorum having been reached.

The AGM adopted all the proposed resolutions, with the exception of the 43^rd resolution which was rejected, in accordance with the recommendations of the Board of Directors.

In particular, the company's shareholders approved the reduction of the directors' term of office from 6 to 3 years and the renewal of the proposed directors' terms of office under these new terms.

The Board of Directors is now composed of 11 members, including 7 independent directors, with terms of office expiring at the end of the Annual General Meeting to be held in 2025.

CARMAT would like to thank all shareholders present, represented or voting by post for their commitment and support.

The consolidated result of the vote by resolution and the minutes of the AGM of May 11, 2022 will be available on the Company's website, under Regulated Information / General Meetings, within the legal deadlines.

●●●

About CARMAT

CARMAT is a French MedTech that designs, manufactures and markets the Aeson artificial heart. The Company’s ambition is to make Aeson the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d’Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of more than 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).